Themis Bioscience is a Vienna-based biotechnology company specializing in the development of vaccines for infectious diseases and cancer. Founded in 2009, Themis utilizes its proprietary Themaxyn® platform, derived from a modified measles virus, to create vaccine candidates that elicit strong immune responses. The company has advanced vaccine programs targeting diseases such as chikungunya, Zika, Lassa fever, and Middle East respiratory syndrome (MERS).
In 2020, Themis was acquired by Merck & Co. (MSD), a move that aimed to accelerate the development of Themis’s vaccine candidates, including those for COVID-19, by leveraging Merck’s global resources and expertise in vaccine development.
